Real-world Evidence for Pembrolizumab in Non-small Cell Lung Cancer: a Nationwide Cohort Study

Overview

Journal Br J Cancer

Specialty Oncology

Date 2024 Nov 3

PMID 39489879

Authors

Helga H Hektoen

Kaitlyn M Tsuruda

Lars Fjellbirkeland

Yngvar Nilssen

Odd Terje Brustugun

Bettina K Andreassen

Affiliations

Soon will be listed here.

Abstract

Background: Based on favourable results from clinical trials, immune checkpoint inhibitors (ICI) have become the standard first line (1 L) systemic anticancer treatment (SACT) for advanced stage non-small cell lung cancer (NSCLC) without targetable mutations. We evaluate whether these results are generalizable to everyday clinical practice and compare overall survival (OS) of patients treated with ICI to a historical cohort of patients treated with chemotherapy and results from clinical trials.

Methods: Our study comprised all advanced NSCLC patients initiating SACT in 2012-21 in Norway. Clinical characteristics and treatment information was retrieved from Norwegian Health Registries.

Results: Survival for all 8416 advanced NSCLC patients treated with SACT increased concurrently with the gradual implementation of ICIs. Median OS of patients treated with 1 L pembrolizumab after 2017 was better (mono-/combination therapy: 13.8/12.8 months) than for patients treated with chemotherapy before 2017 (8.0 months). Although median OS for patients treated with pembrolizumab was lower in clinical practice than clinical trials (Keynote-024/189: 26.3/22.0 months), the survival benefit relative to chemotherapy was similar.

Conclusion: Our nationwide study demonstrated a survival benefit over conventional chemotherapy of a similar magnitude as observed in clinical trials and confirms the effectiveness of pembrolizumab in routine clinical practice.

References

Novello S, Kowalski D, Luft A, Gumus M, Vicente D, Mazieres J . Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study. J Clin Oncol. 2023; 41(11):1999-2006. PMC: 10082300. DOI: 10.1200/JCO.22.01990. View

Guyot P, Ades A, Ouwens M, Welton N . Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012; 12:9. PMC: 3313891. DOI: 10.1186/1471-2288-12-9. View

Boro S, Thoresen S, Helland A . Improvements in survival for patients with stage IV adenocarcinoma in the lung, diagnosed between 2010 - 2020 - A population-based registry study from Norway. Front Oncol. 2022; 12:1017902. PMC: 9745181. DOI: 10.3389/fonc.2022.1017902. View

Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gumus M, Mazieres J . Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 379(21):2040-2051. DOI: 10.1056/NEJMoa1810865. View

Garassino M, Gadgeel S, Speranza G, Felip E, Esteban E, Domine M . Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study. J Clin Oncol. 2023; 41(11):1992-1998. PMC: 10082311. DOI: 10.1200/JCO.22.01989. View

Reck M, Rodriguez-Abreu D, Robinson A, Hui R, Csoszi T, Fulop A . Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016; 375(19):1823-1833. DOI: 10.1056/NEJMoa1606774. View

Thai A, Solomon B, Sequist L, Gainor J, Heist R . Lung cancer. Lancet. 2021; 398(10299):535-554. DOI: 10.1016/S0140-6736(21)00312-3. View

Descourt R, Greillier L, Perol M, Ricordel C, Auliac J, Falchero L . First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study). Cancer Immunol Immunother. 2022; 72(1):91-99. PMC: 10992810. DOI: 10.1007/s00262-022-03232-2. View

Zhou C, Li S, Liu J, Chu Q, Miao L, Cai L . International consensus on severe lung cancer-the first edition. Transl Lung Cancer Res. 2021; 10(6):2633-2666. PMC: 8264326. DOI: 10.21037/tlcr-21-467. View

10.

Chen R, Manochakian R, James L, Azzouqa A, Shi H, Zhang Y . Emerging therapeutic agents for advanced non-small cell lung cancer. J Hematol Oncol. 2020; 13(1):58. PMC: 7245927. DOI: 10.1186/s13045-020-00881-7. View

11.

Pasello G, Pavan A, Attili I, Bortolami A, Bonanno L, Menis J . Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer. Cancer Treat Rev. 2020; 87:102031. DOI: 10.1016/j.ctrv.2020.102031. View

12.

Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F . Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 378(22):2078-2092. DOI: 10.1056/NEJMoa1801005. View

13.

Velcheti V, Hu X, Yang L, Pietanza M, Burke T . Long-Term Real-World Outcomes of First-Line Pembrolizumab Monotherapy for Metastatic Non-Small Cell Lung Cancer With ≥50% Expression of Programmed Cell Death-Ligand 1. Front Oncol. 2022; 12:834761. PMC: 8990758. DOI: 10.3389/fonc.2022.834761. View

14.

Izano M, Sweetnam C, Zhang C, Weese J, Reding D, Treisman J . Brief Report on Use of Pembrolizumab With or Without Chemotherapy for Advanced Lung Cancer: A Real-World Analysis. Clin Lung Cancer. 2023; 24(4):362-365. DOI: 10.1016/j.cllc.2023.01.011. View

15.

Zappa C, Mousa S . Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016; 5(3):288-300. PMC: 4931124. DOI: 10.21037/tlcr.2016.06.07. View

16.

Bakken I, Ariansen A, Knudsen G, Johansen K, Vollset S . The Norwegian Patient Registry and the Norwegian Registry for Primary Health Care: Research potential of two nationwide health-care registries. Scand J Public Health. 2019; 48(1):49-55. DOI: 10.1177/1403494819859737. View

17.

Mouritzen M, Carus A, Ladekarl M, Meldgaard P, Nielsen A, Livbjerg A . Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC-Real World Efficacy. Cancers (Basel). 2021; 13(19). PMC: 8507718. DOI: 10.3390/cancers13194846. View

18.

Rashdan S, Gerber D . Immunotherapy for non-small cell lung cancer: from clinical trials to real-world practice. Transl Lung Cancer Res. 2019; 8(3):202-207. PMC: 6626864. DOI: 10.21037/tlcr.2018.09.15. View

19.

Velcheti V, Hu X, Piperdi B, Burke T . Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices. Sci Rep. 2021; 11(1):9222. PMC: 8080779. DOI: 10.1038/s41598-021-88453-8. View

20.

Shields M, Marin-Acevedo J, Pellini B . Immunotherapy for Advanced Non-Small Cell Lung Cancer: A Decade of Progress. Am Soc Clin Oncol Educ Book. 2021; 41:1-23. DOI: 10.1200/EDBK_321483. View